Cell line · CVCL_1055
A-427
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 49 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. A-427. Cell lines, record CVCL_1055. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1055
On this page
Cell line
As Cellosaurus gives it.
- Name
- A-427
- Accession
- CVCL_1055
- RRID
- RRID:CVCL_1055
- Synonyms
- A427, A427N
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 52Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers49
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. | NPJ Precis Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. | Immunity | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 49
See all 49 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| From the same person | A-427F | CVCL_ZX72 |
Source Cell lines
Cell banks7
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-7906 | Discontinued | Cellosaurus |
| ATCC | HTB-53 | ATCC | |
| AddexBio | C0016004/21 | Cellosaurus | |
| CLS | 300111 | CLS | |
| DSMZ | ACC-234 | DSMZ | |
| IZSLER | BS TCL 120 | Cellosaurus | |
| KCLB | 30053 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1055
GET https://conductscience.org/api/cell-lines/v1/CVCL_1055/papers?page=2